VAVALA', TIZIANA
 Distribuzione geografica
Continente #
NA - Nord America 747
EU - Europa 355
AS - Asia 296
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 1.408
Nazione #
US - Stati Uniti d'America 737
IT - Italia 152
CN - Cina 139
IE - Irlanda 43
SG - Singapore 42
IN - India 37
FR - Francia 29
VN - Vietnam 27
SE - Svezia 21
GB - Regno Unito 17
PL - Polonia 16
UA - Ucraina 15
FI - Finlandia 12
KR - Corea 12
TW - Taiwan 11
CA - Canada 10
JP - Giappone 10
NL - Olanda 10
DE - Germania 9
ID - Indonesia 9
AT - Austria 8
AU - Australia 8
ES - Italia 6
RO - Romania 5
HK - Hong Kong 4
RS - Serbia 3
GR - Grecia 2
PT - Portogallo 2
SA - Arabia Saudita 2
BG - Bulgaria 1
CH - Svizzera 1
CL - Cile 1
CZ - Repubblica Ceca 1
EU - Europa 1
IL - Israele 1
MY - Malesia 1
NO - Norvegia 1
PH - Filippine 1
RU - Federazione Russa 1
Totale 1.408
Città #
Chandler 73
Santa Clara 69
Beijing 67
Fairfield 48
Dublin 43
Wilmington 37
Singapore 35
Pisa 34
Torino 34
Houston 31
Fremont 23
Dong Ket 20
Seattle 18
Cambridge 17
Villeurbanne 17
Woodbridge 17
Warsaw 16
Ashburn 14
Medford 14
Princeton 14
Redwood City 12
Columbus 11
Davis 10
Dearborn 10
Nyköping 10
Jakarta 9
Nanjing 9
Rome 9
Taipei 9
Ann Arbor 8
Chengdu 7
Duncan 7
Turin 7
Vienna 7
Boston 6
Guangzhou 6
Hangzhou 6
Hefei 5
Jacksonville 5
London 5
Norwalk 5
Detroit 4
Guiyang 4
Milan 4
Mumbai 4
Paris 4
San Diego 4
Seoul 4
Toronto 4
Catania 3
Hong Kong 3
Jinan 3
Kyiv 3
Pune 3
Shanghai 3
Silver Spring 3
Bari 2
Boardman 2
Cluj-napoca 2
Ferrara 2
Fuzhou 2
Genoa 2
Giugliano in Campania 2
Gouverneur 2
Hebei 2
Helsinki 2
Kunming 2
Mountain View 2
Sewell 2
Seymour 2
Sydney 2
Tokyo 2
Vicopisano 2
Vieste 2
Acerra 1
Akita 1
Amsterdam 1
Arona 1
Barzanò 1
Bilaspur 1
Bologna 1
Boulder 1
Brescia 1
Brighton-le-sands 1
Bucharest 1
Burlington 1
Cagliari 1
Canberra 1
Central District 1
Changsha 1
Chicago 1
Chieti 1
Cislago 1
Clacton-on-sea 1
Cuneo 1
Dingwall 1
Fallbrook 1
Fontenay-sous-bois 1
Grafing 1
Group 1
Totale 919
Nome #
BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients. Results from a multicenter Italian observational study 370
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 138
Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward? 103
Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer. 100
Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy 98
Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer 96
ROC Analysis Identifies Baseline and Dynamic NLR and dNLR Cut-Offs to Predict ICI Outcome in 402 Advanced NSCLC Patients 96
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 91
Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice 81
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 66
P1.49 (also presented as PD1.05): The Genomics of Young Emergent Lung Cancer: Track: Advanced NSCLC. 64
PD1.05 (also presented as P1.49): The Genomics of Young Emergent Lung Cancer. 63
Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study. 56
The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer 41
Totale 1.463
Categoria #
all - tutte 4.008
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.008


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202097 0 0 0 0 0 23 19 9 18 11 10 7
2020/2021162 9 4 5 11 9 10 12 16 9 19 8 50
2021/2022203 12 7 12 11 8 10 17 10 4 18 71 23
2022/2023195 19 22 2 31 13 51 12 10 15 2 13 5
2023/202490 6 32 5 11 1 2 3 2 0 5 6 17
2024/2025156 4 45 13 16 58 20 0 0 0 0 0 0
Totale 1.463